Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sisram Medical Ltd. ( (HK:1696) ) has provided an announcement.
Sisram Medical Ltd announced strong market momentum in Q3 2025, driven by increased demand in China, South Korea, and Thailand. The company reported a healthy double-digit year-on-year growth in unaudited revenue, with significant orders for its Alma Harmony platform. The company plans to expand the Soprano family in APAC and Universkin sales in the U.S., while preparing for the DAXXIFY launch in China.
The most recent analyst rating on (HK:1696) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
More about Sisram Medical Ltd.
Sisram Medical Ltd, incorporated in Israel, operates in the medical technology industry. The company focuses on providing advanced medical aesthetic solutions, with key products including the Alma Harmony multi-modal platform and the Soprano family of products. It targets markets primarily in the APAC region and the U.S.
Average Trading Volume: 1,683,204
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.19B
For detailed information about 1696 stock, go to TipRanks’ Stock Analysis page.